Reviews medical records of lung cancer patients treated after platinum chemotherapy failed
Reviews past records of adults with non-squamous lung cancer treated after platinum chemotherapy stopped working.
Plain-language title generated from the registry record
Registry title: RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in Brazil
Key facts
- Where
- Belo Horizonte, Natal, Porto Alegre, São José do Rio Preto, and São Paulo, BrazilSee the 5 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced non-squamous non-small cell lung cancer. Their cancer got worse after platinum chemotherapy and they then had more systemic treatment. It reviews past medical records.
- Age
- 18 years or older at diagnosis of advanced or metastatic disease
- Sex
- All sexes can join
- Disease stage
- Non-squamous non-small cell lung cancer, Stage IIIB/IIIC that cannot be cured, or Stage IV/M1
- Earlier treatment
- Platinum-based chemotherapy that failed, then more systemic treatment. With an actionable mutation: at least 1 approved targeted therapy failed, or none was available at the clinic. Without an actionable mutation: immunotherapy given with or after platinum also failed.
- Biomarker or test result
- Two groups: one with actionable mutations and one without actionable mutations
Main reasons for not taking part
- Another primary cancer in the year before the index date (except basal cell carcinoma and melanoma)
- Took part in a clinical investigational study for any cancer from 2018 onwards
- Took part in an early access program from 2018 onwards
Read by machine on 12 November 2026.
Where in Brazil
- Belo HorizonteHospital not named in the registryNot yet recruiting
- NatalHospital not named in the registryTaking people
- Porto AlegreHospital not named in the registryNot yet recruiting
- São José do Rio PretoHospital not named in the registryNot yet recruiting
- São PauloHospital not named in the registryTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- AstraZeneca
- Trial code
- NCT06491862
- Record updated
- 23 September 2026
- Original description
The study will be implemented as a retrospective, noninterventional medical record review of patients from routine practice settings who have been diagnosed with a/m non-squamous NSCLC with or without AGA and received at least 1 line of systemic treatment after failing PTC between January 2017 and December 2024.Read full original descriptionShow less
RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous Non-Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy in Brazil
The study will be implemented as a retrospective, noninterventional medical record review of patients from routine practice settings who have been diagnosed with a/m non-squamous NSCLC with or without AGA and received at least 1 line of systemic treatment after failing PTC between January 2017 and December 2024.
Inclusion: Confirmed diagnosis of non-squamous NSCLC, Stage IIIB/IIIC incurable or IV/M1; Age ≥ 18 years at diagnosis of advanced/metastatic disease; AGA Cohort: Presence of actionable mutations and all of the following:; failure of platinum-based chemotherapy,; failure of ≥ 1 line of approved target therapy or no targeted therapy available at the clinic,; additional systemic treatment after platinum + target therapy combination; Non-AGA Cohort: Absence of actionable mutations and all of the following:; failure of platinum-based chemotherapy,; failure of immunotherapy concurrent or sequential to platinum,; additional systemic treatment after platinum + immunotherapy combination.
Exclusion: Patients with evidence of other primary malignancies (except basal cell carcinoma and melanoma) within 1 year prior to the index date will be excluded from both study cohorts; Patients who participated in a clinical investigational study for the treatment of any cancer, including NSCLC, or any early access program from 2018 onwards.